{"organizations": [], "uuid": "4baea32a97b694733221dcbc047ded7097509632", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/futures", "section_title": "Futures - Markets | Reuters.com", "url": "https://www.reuters.com/article/brief-neos-therapeutics-reiterates-confi/brief-neos-therapeutics-reiterates-confidence-in-strategic-plan-and-value-creation-opportunities-idUSFWN1QA0TK", "country": "US", "domain_rank": 408, "title": "BRIEF-Neos Therapeutics Reiterates Confidence In Strategic Plan And Value Creation Opportunities | Reuters", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.047, "site_type": "news", "published": "2018-02-20T23:43:00.000+02:00", "replies_count": 0, "uuid": "4baea32a97b694733221dcbc047ded7097509632"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-neos-therapeutics-reiterates-confi/brief-neos-therapeutics-reiterates-confidence-in-strategic-plan-and-value-creation-opportunities-idUSFWN1QA0TK", "ord_in_thread": 0, "title": "BRIEF-Neos Therapeutics Reiterates Confidence In Strategic Plan And Value Creation Opportunities | Reuters", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "reuters) - neos therapeutics inc", "sentiment": "neutral"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 20 (Reuters) - Neos Therapeutics Inc:\n* NEOS THERAPEUTICS REITERATES CONFIDENCE IN STRATEGIC PLAN AND VALUE CREATION OPPORTUNITIES\n* NEOS THERAPEUTICS - “CONFIDENT IN CO‘S STRATEGIC PLAN”, IN LIGHT OF PDL BIOPHARMA TERMINATING INTEREST IN CO Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-20T23:43:00.000+02:00", "crawled": "2018-02-20T17:51:19.037+02:00", "highlightTitle": ""}